FRONTEO Inc. (Headquarters: Minato-ku, Tokyo; Representative Board of Director and President: Masahiro Morimoto; hereinafter FRONTEO) has developed a new technology using its in-house specialized AI "KIBIT" for FRONTEO's AI drug discovery support service "Drug Discovery AI Factory (hereinafter "DDAIF")" and obtained a patent in Japan. This technology contributes to solutions such as target discovery, biomarker discovery, and indication discovery in DDAIF. It enables cross-disease pathway analysis and analysis that captures disease stage changes, and is one of the core technologies of DDAIF that contributes to more advanced mechanism of action analysis and improved analysis efficiency. As a result, the number of patents related to DDAIF has increased to 12 in total, including 4 in Japan, 3 in Korea, 2 in the United States, and 21 in Europe.

[Patent outline]
Patent name: Pathway analysis device, pathway analysis method, and pathway analysis program
Patent registration number: Patent No. 7656284
Patent registration date: March 2025, 3

FRONTEO aims to solve these issues through research and development and social implementation of innovative AI and related analytical technologies, thereby contributing to the development of both industry and academia.

About FRONTEO DDAIF
URL: https://lifescience.fronteo.com/products/drug-discovery-ai-factory/
FRONTEO's "Drug Discovery AI Factory (DDAIF)" is an AI drug discovery support service that combines the knowledge of FRONTEO's drug discovery researchers and AI engineers with "KIBIT" (patented in Japan and the US), an AI specialized in natural language processing. It strongly supports researchers' decision-making in drug development by analyzing disease-related gene networks and building hypotheses about target candidates.

This service has already been introduced at several major pharmaceutical companies and is accumulating a proven track record.

[Reference: Co-creation project with pharmaceutical companies]

・ FRONTEO and Chugai Pharmaceutical launch co-creation project for target discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250515
・ EA Pharma and FRONTEO launch co-creation project to explore drug discovery targets using AI, https://www.fronteo.com/pr/20250512
・ FRONTEO and Eisai launch co-creation project for target discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250128
・ FRONTEO and Maruishi Pharmaceutical launch a co-creation project for biomarker discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250109
・ FRONTEO and UBE launch co-creation project on drug repositioning using Drug Discovery AI Factory, https://www.fronteo.com/pr/20241114

[Reference: Joint research projects with academia]

・ FRONTEO and Tokyo University of Science begin joint research into discovering new drug discovery targets using the Drug Discovery AI Factory, https://www.fronteo.com/pr/20250513
・ FRONTEO and Kumamoto University begin joint research to discover new cancer treatments using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250508

■ About FRONTEO Co., Ltd.　URL: https://www.fronteo.com/

FRONTEO supports the judgment of experts in various fields who face social issues day and night through the provision of its proprietary specialized AI "KIBIT," and creates the starting point for innovation. Unlike general-purpose AI, our proprietary natural language processing technology (patented in Japan, the United States, and Europe) enables high-speed and high-precision analysis without relying on the amount of training data or computing power. In addition, by utilizing patented technology that maps (visualizes the structure) the analyzed information, "KIBIT" can directly influence the insights of experts, and in recent years, KIBIT's technology has also been used in hypothesis generation and target discovery in drug discovery.

Through KIBIT's unique technology and approach, we aim to realize our philosophy of "providing solutions that do not overlook risks and opportunities hidden in records, and realizing fairness in the information society."Life science AI, Risk Management (Compliance Support Area,economic security field,Legal Tech AI field), DX (Professional Support Areas) and promotes social implementation in each of our businesses.

Founded in August 2003, listed on the Tokyo Stock Exchange Mothers (now Tokyo Stock Exchange Growth) on June 8, 2007. Has operations in Japan, the United States, South Korea, and Taiwan. Obtained a Type 6 medical device manufacturing and sales license and filed a controlled medical device sales notification. Capital: 26 yen (as of March 899,176, 2025).

*FRONTEO, KIBIT, and Drug Discovery AI Factory are trademarks or registered trademarks of FRONTEO in Japan, Europe, the United States, and Korea.